2. Academic Validation
  3. Pharmacological repression of PPARγ promotes osteogenesis

Pharmacological repression of PPARγ promotes osteogenesis

  • Nat Commun. 2015 Jun 12;6:7443. doi: 10.1038/ncomms8443.
David P Marciano 1,  Dana S Kuruvilla 1,  Siddaraju V Boregowda 1,  Alice Asteian 1,  Travis S Hughes 1,  Ruben Garcia-Ordonez 1,  Cesar A Corzo 1,  Tanya M Khan 1,  Scott J Novick 1,  HaJeung Park 1,  Douglas J Kojetin 1,  Donald G Phinney 1,  John B Bruning 2,  Theodore M Kamenecka 1,  Patrick R Griffin 1
Affiliations

Affiliations

  • 1 Departments of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, Jupiter FL33458, USA.
  • 2 School of Molecular and Biomedical Science, The University of Adelaide, Adelaide, SA 5005, Australia.
PMID: 26068133 DOI: 10.1038/ncomms8443
Abstract

The nuclear receptor Peroxisome Proliferator-activated Receptor gamma (PPARγ) is the master regulator of adipogenesis and the pharmacological target of the thiazolidinedione (TZD) class of Insulin sensitizers. Activation of PPARγ by TZDs promotes adipogenesis at the expense of osteoblast formation, contributing to their associated adverse effects on bone. Recently, we reported the development of PPARγ Antagonist SR1664, designed to block the obesity-induced phosphorylation of serine 273 (S273) in the absence of classical agonism, to derive insulin-sensitizing efficacy with improved therapeutic index. Here we identify the structural mechanism by which SR1664 actively antagonizes PPARγ, and extend these findings to develop the inverse agonist SR2595. Treatment of isolated bone marrow-derived mesenchymal stem cells with SR2595 promotes induction of osteogenic differentiation. Together these results identify the structural determinants of ligand-mediated PPARγ repression, and suggest a therapeutic approach to promote bone formation.

Figures
Products